Welcome to AstraZeneca United States
We push the boundaries of science to deliver life-changing medicines
Latest News from AstraZeneca US
PT027, a novel fixed-dose combination of albuterol and budesonide, used as an as-needed rescue medicine, significantly reduced the risk of a severe exacerbation compared to albuterol by 27% in patients with asthma
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen
FARXIGA met primary endpoint in DELIVER Phase III trial, reducing risk of cardiovascular death or worsening heart failure in patients with preserved ejection fraction
ULTOMIRIS® (ravulizumab-cwvz) met primary endpoint in CHAMPION-NMOSD Phase III trial in adults with neuromyelitis optica spectrum disorder
Imfinzi plus chemotherapy granted Priority Review in the US for patients with locally advanced or metastatic biliary tract cancer based on TOPAZ-1 Phase III trial
We want to transform healthcare, change the lives of billions of people for the better and address some of the biggest healthcare challenges facing humankind. Our ambition is to stop the progress of these often degenerative, debilitating, and life-threatening conditions, achieve remission, and one day cure them.
Oncology: Start with One
At AstraZeneca, we are leading a revolution in oncology to redefine cancer care for the millions of Americans living with cancer. It’s a lofty ambition. But we know that as with every great journey, the road always starts with one—one indication that can change the course of disease for a patient, one person living with cancer that benefits from our support services, one access barrier that we can help to overcome, one system to transform in partnership with the community—and then another, building from there until success is achieved. Click below to read more about this next chapter.
If you are passionate about science, these stories will show you how the latest and most exciting projects we have been working on and the people behind them.